Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aardvark Therapeutics, Inc.AARD · Entity 6598 | Director | August 14, 2026 | August 21, 2026 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | June 23, 2022 | June 27, 2022 |
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Chief Medical Officer | March 02, 2026 | March 04, 2026 |
| Natera, Inc.NTRA · Entity 2635 | Director | June 26, 2026 | July 01, 2026 |
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | June 12, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aardvark Therapeutics, Inc.
Report date August 14, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.54 · Expires 2036-08-14 | Direct | 44,964 |
Reported balance
After 2026-08-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 44,964 · Balance 44,964 F1: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.
Atara Biotherapeutics, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,500 |
Reported balance
After 2022-06-23 transaction · row 1
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 20,500 · Balance 43,500 F1: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.35 · Expires 2032-06-22 | Direct | 31,500 |
Reported balance
After 2022-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-23 · Grant · Acquired 31,500 · Balance 31,500 F2: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
F2: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 134,088 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 134,088 · Balance 134,088 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Natera, Inc.
Report date June 26, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,158 |
Ending reported balance
After 2026-06-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-26 · Grant · Acquired 1,571 · Balance 20,083 F1: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 11, 2027. The RSUs will become fully vested in the event that the Issuer is subject to a change in control. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-06-26 · Grant · Acquired 75 · Balance 20,158 F3: Represents the issuance of RSUs to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 11, 2027. The RSUs will become fully vested in the event that the Issuer is subject to a change in control.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: Represents the issuance of RSUs to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Travere Therapeutics, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,500 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-12 · Exercise / conversion · Acquired 4,500 · Balance 46,000 Row 2 · 2026-06-12 · Sale · Disposed 4,500 · Balance 41,500 F1: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.38 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Exercise / conversion · Disposed 4,500 · Balance 0 F2: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
F2: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2022 Filed May 13, 2022 00:18 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028685 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 23:03 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001140361-21-020429 · form4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-07 F2 · derivative.exercise_date: The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 23:03 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-020429 · form4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 F1 · shares: These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 23:58 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 2,614 | $0.00 Strike: $94.14 | $0.00 |
DisclosureSEC source: 0001415889-21-002767 · form4-06022021_040601.xml · derivative · entry 4 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,614 Underlying: Common Stock · 2,614 shares Expires 2031-05-27 F4 · derivative.exercise_date: The option shares shall vest and become exercisable in full on May 25, 2022. The option shares will become fully vested and exercisable in the event that the Issuer is subject to a change in control. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 23:58 UTC | Natera, Inc. NTRA · Entity 2635 | GrantRestricted Stock Unit · Derivative | 1,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002767 · form4-06022021_040601.xml · derivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,307 Underlying: Common Stock · 1,307 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSU shall vest in full on May 25, 2022. The RSU will become fully vested in the event that the Issuer is subject to a change in control. F3 · derivative.expiration_date: The RSU shall vest in full on May 25, 2022. The RSU will become fully vested in the event that the Issuer is subject to a change in control. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 23:58 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionRestricted Stock Unit · Derivative | 2,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002767 · form4-06022021_040601.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,856 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSU vested in full on May 28, 2021. F2 · derivative.expiration_date: The RSU vested in full on May 28, 2021. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 23:58 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 2,856 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-21-002767 · form4-06022021_040601.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:25 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001209191-21-033853 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-05-13 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:25 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033853 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 22:20 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionStock Option (right to buy) · Derivative | 1,300 | $0.00 Strike: $24.42 | $0.00 |
DisclosureSEC source: 0001179110-20-008903 · edgar.xml · derivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,230 Underlying: Common Stock · 1,300 shares Expires 2028-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option shares vest over three years. A third of the option shares vested and became exercisable on July 25, 2019 with the remaining shares vesting in 2 equal annual installments thereafter. The initial option will become fully vested and exercisable in the event that the Company is subject to a change in control. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 22:20 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 1,300 | $53.47 | $69,512.95 |
DisclosureSEC source: 0001179110-20-008903 · edgar.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.35 to $53.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 22:20 UTC | Natera, Inc. NTRA · Entity 2635 | Exercise / conversionCommon Stock | 1,300 | $24.42 | $31,746.00 |
DisclosureSEC source: 0001179110-20-008903 · edgar.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 24,500 | $0.00 Strike: $10.54 | $0.00 |
DisclosureSEC source: 0001209191-20-037364 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2030-06-15 F2 · derivative.exercise_date: The option shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037364 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · shares: These restricted stock units shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 22:41 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 5,712 | $0.00 Strike: $40.93 | $0.00 |
DisclosureSEC source: 0001179110-20-007463 · edgar.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,712 Underlying: Common Stock · 5,712 shares Expires 2030-06-11 F3 · derivative.exercise_date: The option shares shall vest and become exercisable in full on May 28, 2021. The option shares will become fully vested and exercisable in the event that the Issuer is subject to a change in control. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 22:41 UTC | Natera, Inc. NTRA · Entity 2635 | GrantRestricted Stock Units · Derivative | 2,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007463 · edgar.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,856 Underlying: Common Stock · 2,856 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The RSU shall vest in full on May 28, 2021. The RSU will become fully vested in the event that the Issuer is subject to a change in control. F2 · derivative.expiration_date: The RSU shall vest in full on May 28, 2021. The RSU will become fully vested in the event that the Issuer is subject to a change in control. Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030743 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030743 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 20:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-19-039762 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-26 F2 · derivative.exercise_date: The option shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 20:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039762 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · shares: These restricted stock units shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 24, 2019 Filed May 29, 2019 22:15 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $22.83 | $0.00 |
DisclosureSEC source: 0001179110-19-006814 · edgar.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-05-23 F1 · derivative.exercise_date: The option shares will vest and become exercisable in full on the earlier of (x) the date that is 12 months following the date of grant (May 24, 2019) or (y) the date of the annual stockholder meeting next following the grant. The option shares will become fully vested and exercisable in the event that the Company is subject to a change in control. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:33 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029152 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:33 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029152 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 22:33 UTC | Natera, Inc. NTRA · Entity 2635 | GrantStock Option (right to buy) · Derivative | 16,530 | $0.00 Strike: $24.42 | $0.00 |
DisclosureSEC source: 0001179110-18-011531 · edgar.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,530 Underlying: Common Stock · 16,530 shares Expires 2028-09-13 F1 · derivative.exercise_date: The option shares vest over three years. A third of the option shares vest and become exercisable on July 25, 2019 and the remaining shares vest on 2 equal annual installments thereafter. The initial option will become fully vested and exercisable in the event that the Company is subject to a change in control. Read SEC document |
| September 11, 2018 Filed Sep 12, 2018 21:57 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $41.05 | $0.00 |
DisclosureSEC source: 0001209191-18-050690 · doc4.xml · derivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2025-09-10 F1 · derivative.exercise_date: 1/3rd of the shares will vest on the first, second and third anniversaries of the grant date, subject to the Director's Continuous Service (as defined in the Plan). Read SEC document |
| May 09, 2018 Filed May 12, 2018 01:10 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $26.52 | $0.00 |
DisclosureSEC source: 0001209191-18-029724 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-08 F1 · derivative.exercise_date: The option shall vest in 4 equal quarterly installments following the date of grant. Read SEC document |
| May 09, 2018 Filed May 12, 2018 01:10 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-029724 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001209191-17-033721 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option shall vest in 4 equal quarterly installments following the date of grant. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033721 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.